Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hologic/Grifols, Roche Molecular Zika Tests Tapped For Blood-Screening Ramp-Up

Executive Summary

A blood-screening test made by Hologic in collaboration with Grifols, and another made by Roche Molecular Diagnostics, are being used in a gradual ramp-up of Zika virus screening at blood donation centers across the US under a new FDA program.

You may also be interested in...



FDA Approves Roche Molecular Cobas Test As Zika Virus Blood Donor Screen

US FDA approved Roche Molecular Diagnostics' cobas Zika virus test to screen plasma specimens from blood and organ donors.

Blood Brothers No More: Hologic Unloads Blood-Screening Business To Partner Grifols

Hologic's partner in the blood-screening business, Grifols SA, will buy-out Hologic's share for $1.85bn. Grifols already owns all the customer-facing parts of the business; it will now take on research, development and manufacture of assays and instruments based on nucleic acid testing for transfusion and transplantation screening.

Short-Term US Funding Bill Passes With $1.1bn In Emergency Zika Funds

Congress managed to settle its disputes over funding riders Sept. 28 and passed a relatively clean bill that contains $1.1bn in emergency Zika virus response funding, and will keep government agencies – including US FDA – running at current spending levels until Dec. 9.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT103768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel